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Risk Factors for Pre-Treatment Mortality among HIVInfected Children in Rural Zambia: A Cohort Study
Catherine G. Sutcliffe1*, Janneke H. van Dijk2, Bornface Munsanje2, Francis Hamangaba2, Pamela
Siniwymaanzi2, Philip E. Thuma2, William J. Moss1
1 Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America, 2 Macha Research Trust,
Macha Hospital, Choma, Zambia

Abstract
Background: Many HIV-infected children in sub-Saharan Africa enter care at a late stage of disease. As preparation of the
child and family for antiretroviral therapy (ART) can take several clinic visits, some children die prior to ART initiation. This
study was undertaken to determine mortality rates and clinical predictors of mortality during the period prior to ART
initiation.
Methods: A prospective cohort study of HIV-infected treatment-naı̈ve children was conducted between September 2007
and September 2010 at the HIV clinic at Macha Hospital in rural Southern Province, Zambia. HIV-infected children younger
than 16 years of age who were treatment-naı̈ve at study enrollment were eligible for analysis. Mortality rates prior to ART
initiation were calculated and risk factors for mortality were evaluated.
Results: 351 children were included in the study, of whom 210 (59.8%) were eligible for ART at study enrollment. Among
children ineligible for ART at enrollment, 6 children died (mortality rate: 0.33; 95% CI:0.15, 0.74). Among children eligible at
enrollment, 21 children died before initiation of ART and their mortality rate (2.73 per 100 person-years; 95% CI:1.78, 4.18)
was significantly higher than among children ineligible for ART (incidence rate ratio: 8.20; 95% CI:3.20, 24.83). In both
groups, mortality was highest in the first three months of follow-up. Factors associated with mortality included younger age,
anemia and lower weight-for-age z-score at study enrollment.
Conclusions: These results underscore the need to increase efforts to identify HIV-infected children at an earlier age and
stage of disease progression so they can enroll in HIV care and treatment programs prior to becoming eligible for ART and
these deaths can be prevented.
Citation: Sutcliffe CG, van Dijk JH, Munsanje B, Hamangaba F, Siniwymaanzi P, et al. (2011) Risk Factors for Pre-Treatment Mortality among HIV-Infected Children
in Rural Zambia: A Cohort Study. PLoS ONE 6(12): e29294. doi:10.1371/journal.pone.0029294
Editor: Landon Myer, University of Cape Town, South Africa
Received August 5, 2011; Accepted November 24, 2011; Published December 21, 2011
Copyright: ß 2011 Sutcliffe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was made possible by support from the President’s Emergency Plan for AIDS Relief (PEPFAR) through Cooperative Agreement U62/
CCU322428 from the Department of Health and Human Services (DHHS)/Centers for Disease Control and Prevention (CDC), Global AIDS Program. The findings
and conclusions included in its content are solely the responsibility of the author(s) and do not necessarily represent the official position of the Centers for Disease
Control and Prevention/Agency for Toxic Substances and Disease Registry. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: csutclif@jhsph.edu

friend to provide support (‘medicine companion’ or ‘treatment
supporter’) [4,5,6,7]. During this time, children also are diagnosed
and treated for any concurrent opportunistic infections. In
addition, children not eligible for ART at enrollment are
monitored, typically every three months, and may experience
rapid disease progression. Few programs report outcomes during
this period prior to ART initiation, but several studies among
adults [5,7,8,9,10,11] and children [3,6,12,13] indicate that
significant mortality occurs among both ART eligible and
ineligible individuals during this time of preparation and
evaluation.
This study was undertaken to determine mortality rates and
identify clinical predictors of mortality during the period prior to
ART initiation among both eligible and ineligible children
enrolled in an ART program in rural Zambia.

Introduction
Since 2003, antiretroviral treatment (ART) programs in subSaharan Africa have rapidly scaled-up and currently provide
treatment to an estimated 356,000 HIV-infected children [1].
Reports from programs indicate that treatment outcomes among
children are comparable to those observed in resource-rich settings
[2]. However, many children enter care at a late stage of disease
progression, such that mortality rates during the first few months
of treatment are high [2]. The period between enrollment into
care and treatment initiation can extend for several months as
eligible children and their families are prepared for the burden and
challenges of ART [3]. This process can involve several clinic and
home visits, psychological assessments, ART literacy training,
adherence counseling, and identification of a family member or
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included. Children were followed until the first of either ART
initiation, death, loss to follow-up or September 1, 2010. Children
whose last visit occurred more than six months prior to September
1, 2010 were considered lost to follow-up.

Methods
Ethics Statement
The study was approved by the Government of Zambia
Ministry of Health, the Research Ethics Committee of the
University of Zambia and the Institutional Review Board of the
Johns Hopkins Bloomberg School of Public Health. Written
informed consent was obtained from parents or guardians and
assent was obtained from children 8–16 years of age.

Table 1. Baseline characteristics of treatment-naı̈ve, HIVinfected children receiving care at Macha Hospital, Zambia
from 2007–2010.

Study Population
The study was conducted at Macha Hospital in a rural area of
Southern Province, Zambia. The study setting and population
have been described in detail elsewhere [14,15]. Briefly, Macha
Hospital is a district-level referral hospital administered by the
Zambian Brethren in Christ Church. Since 2005, Macha Hospital
has provided care to over 7000 HIV-infected adults and children
through the Government of Zambia’s antiretroviral treatment
program, with additional support from the President’s Emergency
Plan for AIDS Relief (PEPFAR) through the non-governmental
organization, AidsRelief.
Children with a positive HIV serologic test are referred to the
clinic from voluntary counseling and testing programs, outpatient
clinics and rural health centers. Early infant diagnosis based on
detection of HIV DNA has been available since February 2008.
Clinical care is provided without charge by medical doctors and
clinical officers, and adherence counseling by nurses and trained
counselors. Routine follow up occurs approximately every three
months. ART is initiated according to WHO guidelines at the
discretion of the doctors and clinical officers. At enrollment in the
clinic, children and their caregivers must attend two group
counseling sessions to avoid early attrition. Before ART initiation
an individual treatment preparation counseling session is provided,
and children must demonstrate their ability to adhere to non-ART
medications, including multivitamins and cotrimoxazole, over two
visits through self-report and pill counts. In addition, individuals
must identify a family member or friend to serve as a treatment
supporter.

Study population
(n = 351) N (%)
Median age in years (IQR)(n = 351)

2.6 (1.4, 5.7)

,2 yrs

140 (39.9)

2–4 yrs

109 (31.1)

$5 yrs

102 (29.1)

Male (n = 351)

158 (45.0)

Mother received PMTCT (n = 348)

22 (6.3)

Vital status of parents (n = 347)
Both alive

264 (76.1)

One parent died

64 (18.4)

Both died

19 (5.5)

Primary caregiver (n = 348)
Mother/Father

272 (78.2)

Grandparent

39 (11.2)

Aunt/uncle

26 (7.5)

Other

11 (3.2)

Education of primary caregiver (n = 337)
None

12 (3.6)

Primary

211 (62.6)

Secondary

110 (32.6)

Higher

4 (1.2)

Socioeconomic status (n = 348)

Study Procedures
Beginning in September 2007, HIV-infected children younger
than 16 years seeking HIV care were eligible for enrollment into a
cohort study. Children were evaluated at study visits approximately every three months, at which time a questionnaire was
administered, the child was examined and a blood specimen was
obtained. The study questionnaire was designed to collect
information on demographics, the vital status and education of
the parents and primary caregiver, the child’s medical, medication, and vaccination history, disclosure of HIV status and
transportation to the clinic. During each physical examination,
height and weight were measured. As part of routine clinical care,
CD4+ T cell counts and percentages were measured using the
Guava Easy CD4 system (Guava Technologies, Inc., Hayward,
CA). Hemoglobin was measured using an ABX Micros ES 60
Hematology Analyzer (Horiba Medical, France). For children who
missed study visits, home visits were attempted to ascertain their
status. For children who died, cause of death was ascertained
through verbal autopsy or through hospital or clinic records.
Information recorded before study enrollment was abstracted from
medical records.

233 (67.0)

26–50th percentile

96 (27.6)

51–75th percentile

17 (4.9)

76–100th percentile

2 (0.6)

Median WAZ (IQR)a (n = 283)

22.2 (23.4, 21.3)

$22

133 (45.9)

,22 to 23

70 (24.1)
87 (30.0)

,23
Median CD4% (IQR) (n = 320)
Severe immunodeficiencyb

20.7 (14.7, 27.6)
129 (40.3)

WHO stage (n = 264)
1

50 (18.9)

2

78 (29.6)

3 or 4

136 (51.5)

Eligible for ARTc (n = 351)

210 (59.8)

ART: antiretroviral treatment ; IQR: interquartile range; PMTCT: prevention of
mother-to-child transmission; WAZ: weight-for-age z-score; WHO: World Health
Organization.
a
Among children ,10 years of age.
b
Defined by age for all children according to the 2006 WHO guidelines.
c
Defined retrospectively according to the WHO treatment guidelines in effect at
the time of study enrollment.
doi:10.1371/journal.pone.0029294.t001

Statistical Analysis
For the present analysis, all treatment-naı̈ve children enrolled in
the study between September 2007 and September 2010 were
PLoS ONE | www.plosone.org
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Figure 1. Outcomes at the end of the study period, by eligibility status at study enrollment.
doi:10.1371/journal.pone.0029294.g001

Treatment guidelines were revised in 2008 [17], and ART was
recommended for all children younger than 12 months of age. For
children older than 12 months, ART initiation was based on
clinical (WHO stage 3 or 4) and immunologic (WHO stage 1 or 2
and ,20% for children 12–59 months or ,15% for children $5
years of age) status. The 2008 WHO treatment guidelines were
assumed to take effect in June, 2008. For children missing WHO
stage or CD4+ T-cell percentage at enrollment, ART eligibility

Eligibility for ART at study enrollment was defined retrospectively based on the WHO criteria in effect at the time of study
enrollment. At the beginning of the study, the 2006 WHO
treatment guidelines were in effect [16], which recommended
ART for all children with WHO stage 3 or 4 irrespective of
immunologic status. For children with WHO stage 1 or 2, ART
was recommended on the basis of immunologic status (#11
months: ,25%; 12–35 months: ,20%; $36 months: 15%).

Figure 2. Cumulative probability of ART initiation by eligibility status at study enrollment.
doi:10.1371/journal.pone.0029294.g002
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was defined based on immunologic or clinical criteria alone.
Immunologic and clinical parameters from within three months of
study enrollment were used to determine ART eligibility and
clinical and immunologic status at study enrollment. Weight-forage z-scores were calculated based on the WHO growth standards
[18] and children with z-scores below 22 and 23 were defined as
underweight and severely underweight, respectively. Severe
immunodeficiency was defined as CD4+ T-cell percentage by
age for all children according to the 2006 WHO treatment
guidelines (#11 months: ,25%; 12–35 months: ,20%; 36–59
months: ,15%; $5 years: ,15%) [16]. Severe anemia was
defined as hemoglobin ,8 g/dL [19]. A measure of socioeconomic status (SES) was calculated based on the Demographic
and Health Survey SES scale used in Zambia [20]. SES
percentiles were based on the predetermined cutoffs (,25th = 0–
6; 26–50th = 7–12; 51–75th = 13–18; .75th = 19–24).
Kaplan-Meier survival methods were used to estimate the
cumulative probability of ART initiation and death. Survival
curves were compared between groups using the logrank test.
Mortality rates were calculated per 100 person-years at risk and
were compared using Poisson regression. Risk factors for mortality
were evaluated using Cox proportional hazards regression.
Characteristics associated with mortality in univariable analysis
(p,0.1) were considered for inclusion in the multivariable model.
All analyses were conducted in SAS for Windows version 9.2 (SAS
Institute Inc., Cary, NC) and Stata, version 11 (StataCorp LP,
College Station, Texas).

Results
During the study period, 363 treatment-naı̈ve HIV-infected
children were invited to participate and 362 were enrolled. Three
hundred and fifty-one (97%) children had sufficient information to
determine their eligibility for ART and were included in the
analysis. Children were enrolled in the clinic for a median of 0.20
months (interquartile range [IQR]: 0, 4.16) prior to study
enrollment, and the median follow-up time in the study was
3.44 months (IQR: 0.92, 9.44). At study enrollment, the median
age was 2.6 years (IQR: 1.4, 5.7), 45.1% of children were male,
and 23.5% of children were single or double orphans (Table 1).
Over half (54.0%) of children were moderately (24.1%) or severely
underweight (30.0%) and the majority had severe disease: 40.3%
had severe immunodeficiency, 51.5% were classified as WHO
stage 3 or 4, and 59.8% were eligible for ART.
By the end of the study period, 192 (54.7%) children started
ART, 15 (4.3%) were lost to follow-up, 9 (2.6%) transferred to
another clinic, 27 (7.7%) died, and 108 (30.8%) were still in care
but not receiving ART. Children eligible for ART at enrollment
were significantly more likely to have started ART (p,0.0001)
and died (p = 0.05) (Figure 1). Among children eligible at
enrollment, the median time from study enrollment to ART
initiation was 2.07 months (IQR: 0.92, 6.59) (Figure 2). At 12 and
24 months, the cumulative probability of ART initiation was
84.1% and 88.0%, respectively. Chart reviews were conducted
for 69 children who had either taken more than three months to

Table 2. Evaluation of delays in ART initiation among 69 children eligible for ART at enrollment who had either taken more than
three months to initiate ART or had been enrolled in the study for more than 3 months without starting ART.

N (%)
Delayed ART initiation

56 (81.2)

Family delay

19 (33.9)

Poor adherence
Family unpreparedness

3 (5.4)
a

4 (7.1)

Family unpreparedness and poor adherence

8 (14.3)

Child stopped coming to the clinic

4 (7.1)

Provider delay

16 (28.6)

Misinterpretation of laboratory results, HIV staging or eligibility criteria by clinician

10 (17.9)

Other

6 (10.7)

Medical delay

11 (19.6)

Hepatitis or elevated ALT

1 (1.8)

Tuberculosis

10 (17.9)

Combined family, provider or medical delay

9 (16.1)

Provider and family delay

6 (10.7)

Tuberculosis and poor adherence

2 (3.6)

Tuberculosis and family unpreparedness

1 (1.8)

Unknown

1 (1.8)

No delay

13 (18.8)

Eligible by WHO stage onlyb

10 (76.9)

Other

3 (23.1)

Total

69 (100.0)

ART: antiretroviral treatment; ALT: alanine aminotransferase; WHO: World Health Organization.
a
Family unpreparedness included refusal to come at shorter intervals and problems with transportation.
b
Children who are underweight or have specific symptoms and opportunistic infections (e.g. prolonged diarrhea) are classified as WHO stage 3 at that visit. However,
they are not considered eligible for ART if their weight or symptoms improve with treatment at subsequent visits.
doi:10.1371/journal.pone.0029294.t002
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(incidence rate ratio: 8.20; 95% CI: 3.20, 24.83). The mortality
rate was highest in the first three months after study enrollment
at 2.58 per 100 person-years (95% CI: 1.65, 4.05), and was
higher among children eligible for ART (eligible: 4.50; 95% CI:
2.75, 7.34; ineligible: 0.79; 95% CI: 0.25, 2.44; incidence rate
ratio: 5.70; 95% CI: 1.63, 30.55). Twenty-one (77.8%) of the
children who died were eligible for ART at study enrollment,
and this group was therefore more similar in characteristics at
study enrollment to the surviving children eligible for ART
(Table 3).
Among children eligible for ART at study enrollment, age,
WAZ score and anemia were associated with mortality in the
crude analysis and were further evaluated. In multivariable
analysis, lower WAZ score (HR for ,23 vs. $22: 7.63; 95%
CI: 1.80, 32.39) and anemia (HR: 3.50; 95% CI: 1.25, 9.77)
remained independently associated with a higher risk of mortality
(Table 4). Younger age was marginally independently associated
with mortality (hazard rate [HR] for ,2 years vs. $5 years: 3.58;
95% CI: 0.98, 13.09). CD4+ T-cell percentage at study enrollment
and sex were not associated with mortality. The cumulative
probability of mortality six months after study enrollment was
8.0% for children with WAZ$22, 24.3% for children with WAZ
23 to 22, and 35.0% for children with WAZ,23 (logrank
test = 0.04; Figure 4A). The cumulative probability of mortality six
months after enrollment was 13.8% for children without anemia
and 34.6% for children with anemia (logrank test = 0.001;
Figure 4B). The cumulative probability of mortality six months
after enrollment was 33.7% for children younger than 2 years of
age, 4.5% for children 2 to 4 years of age, and 9.2% for children 5
years of age or older (logrank test = 0.01; Figure 4C). Similar risk
factors were found among children who were ineligible for ART at
study enrollment, although the number of children and deaths
were small and precluded a full evaluation (Table 4).

initiate ART or had been enrolled in the study for more than
three months without starting ART to determine reasons for
potential delays in ART initiation (Table 2). The majority of
children (81.2%) were found to have an identifiable reason for
delay. The most common reason was delay on the part of the
family (33.9%), due to poor adherence of the child to other
medications, family unpreparedness to adhere to the more
frequent clinic visit schedule or the child missing clinic visits.
Other reasons included provider delay (28.6%), primarily due to
misinterpretation of laboratory results, HIV staging or eligibility
criteria by clinicians; medical delay (19.6%), primarily due to
treatment for tuberculosis; and a combination of family, provider
and medical delays (16.1%). Among children ineligible at
enrollment, the cumulative probability of ART initiation at 12
and 24 months was 35.3% and 41.0%, respectively (Figure 2).
Among the 27 children who died, the median time from study
enrollment to death was 1.90 months (IQR: 0.36, 3.41). Factors
contributing to death were available for 25 children and included
pneumonia (n = 10), tuberculosis (n = 10), undernutrition
(n = 10), diarrhea (n = 8), cerebral malaria (n = 1), meningitis
(n = 2), renal failure (n = 1), hepatitis (n = 1) and measles (n = 1).
Place of death was available for 21 children; 16 (76.2%) children
died in the hospital and 5 (23.8%) children died at home. The
cumulative probabilities of death by 6, 12 and 24 months after
study enrollment were 9.9% (18.6% eligible, 3.2% ineligible),
12.0% (18.6% eligible, 6.1% ineligible), and 13.4% (24.4%
eligible, 6.1% ineligible; logrank test = 0.0003; Figure 3), respectively. The overall pre-ART mortality rate was 1.05 (95% CI:
0.72, 1.53) per 100 person-years. Among children ineligible for
ART, the mortality rate was 0.33 (95% CI: 0.15, 0.74) per 100
person-years. Among children eligible for ART, the mortality
rate was 2.73 (95% CI: 1.78, 4.18) per 100 person-years and was
significantly higher than among children ineligible for ART

Figure 3. Cumulative probability of mortality by eligibility status at study enrollment.
doi:10.1371/journal.pone.0029294.g003
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Table 3. Comparison of characteristics at study enrollment between children who died, and children who were eligible and
ineligible for ART at study enrollment.

Children who died
(n = 27) N (%)

Surviving children
eligible for ARTa
(n = 189) N (%)

p-value

Male

10 (37.0)

87 (46.0)

Median age (IQR)

Surviving children
ineligible for ARTa
(n = 135) N (%)

p-valueb

0.38

61 (45.2)

0.44

0.07

4.3 (2.1, 7.0)

,0.0001

b

1.4 (0.7, 2.6)

2.0 (1.1, 4.7)

,2 yrs

18 (66.7)

91 (48.2)

2–4 yrs

5 (18.5)

55 (29.1)

$5 yrs

4 (14.8)

43 (22.8)

0.20

55 (40.7)

,0.0001

23.7 (24.4, 22.1)

22.3 (23.6, 21.4)

0.03

21.8 (22.6, 20.9)

0.0002

$22

4 (21.1)

70 (42.9)

,22 to 23

4 (21.1)

35 (21.5)

,23

11 (57.9)

58 (35.6)

0.12

18 (16.7)

0.0003

20.7 (14.9, 26.8)

17.0 (10.5, 21.1)

0.03

25.8 (22.1, 33.3)

0.001

10 (41.7)

119 (67.2)

0.01

0 (0.0)

,0.0001

8.9 (7.7, 9.3)

9.5 (8.6, 10.5)

0.001

10.6 (9.3, 11.3)

,0.0001

8 (33.3)

21 (11.6)

0.004

7 (5.9)

,0.0001

Median WAZ (IQR)c

Median CD4% (IQR)
Severe immunodeficiencyd
Median hemoglobin (IQR)
,8 g/dL

31 (23.0)
49 (36.3)

59 (54.6)
31 (28.7)

WHO stage
1

1 (5.3)

11 (7.1)

38 (41.3)

2

3 (15.8)

21 (13.7)

54 (58.7)

3 or 4

15 (78.9)

121 (79.1)

Both alive

19 (73.1)

151 (79.9)

One parent died

7 (26.9)

28 (14.8)

Both died

0 (0.0)

10 (5.3)

0.51

0 (0.0)

,0.0001

Parent’s vital status
94 (71.2)
29 (22.0)
0.18

9 (6.8)

0.36

ART: antiretroviral treatment; WAZ: weight-for-age z-score; WHO: World Health Organization.
a
ART eligibility defined retrospectively according to the WHO treatment guidelines in effect at the time of study enrollment.
b
p-value comparing surviving children to children who died.
c
Among children ,10 years of age.
d
Defined by age according to the 2006 WHO guidelines.
doi:10.1371/journal.pone.0029294.t003

median of 605 days [13]. Most events, three of which were deaths,
occurred within the first year of follow-up. Predictors of
progression included lower CD4+ T-cell percentage, higher viral
load, and younger age. Anemia was marginally associated with
progression but WAZ was not associated. Additional studies
reported that 1% of eligible and 3% of ineligible children in
Zambia died prior to ART initiation [3], and that 12.3% of ARTnaı̈ve children compared to 9.5% of children on ART in
Mozambique died during follow-up [12]. Similar trends of high
pre-ART mortality in the first few months of follow-up and similar
risk factors were also found in studies of HIV-infected adults
[5,7,8,9,10]. In this study, the cumulative mortality prior to ART
initiation was 13.3% and was comparable to the cumulative
mortality of 14.4% among children initiating ART in this cohort
[15]. In addition, the mortality rate in the first three months after
study enrollment among children eligible for ART was comparable to the mortality rate in the first three months after ART
initiation (unpublished data). While mortality rates differ between
programs depending on the characteristics of the population and
the rigor of ascertainment of deaths, these estimates indicate that a
significant proportion of children entering care are dying before
they initiate ART.
The majority of deaths occurred in the first few months after
study enrollment and during the period of preparation for ART.
The median time to ART initiation among eligible children was

Discussion
Mortality among HIV-infected children in the period prior to
ART initiation was high, particularly in the first few months after
enrollment among children eligible for ART. Risk factors for
mortality included younger age, undernutrition and anemia, and
were similar among children eligible and ineligible for ART at
study enrollment.
Most treatment programs report on mortality and treatment
outcomes after initiation of ART and few have focused on the
period prior to ART initiation. However, this period should be
evaluated along with the interval after ART initiation as it
provides additional insight into the population of children reached
by the program and the effectiveness of the treatment program in
reducing mortality. A study of HIV-infected children from
Cambodia evaluated mortality prior to and after ART initiation
and found that the majority of deaths occurred before starting
ART [6]. Similar to this study, the majority of deaths occurred
within the first three months after enrollment and among children
who were eligible for ART. The overall mortality rate for children
who never started ART was 7.7 per 100 person-years and was
higher than the mortality rate among children receiving ART (2.0
per 100 person-years). Another study among 192 Ugandan
children who were ineligible for ART found that 19% progressed
to a WHO stage 3 or 4 event, death or ART eligibility after a
PLoS ONE | www.plosone.org
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Table 4. Risk factors for mortality among children eligible and ineligible for ART at study enrollment.

Children eligible for ART (n = 210; 21 deaths)

Male

Children ineligible for ART
(n = 141; 6 deaths)

Crude HR (95% CI)

Adjusted HR (95% CI)

Crude HR (95% CI)

0.53 (0.20, 1.37)

—

2.47 (0.45, 13.49)

Age (years)
,2

3.31 (0.96, 11.42)

3.58 (0.98, 13.09)

3.90 (0.35, 43.23)

2–4

0.63 (0.11, 3.78)

1.03 (0.16, 6.60)

3.29 (0.34, 31.74)

$5

1

1

Weight-for-age z-scorea

1

0.74 (0.54, 1.01)

0.48 (0.26, 0.91)

$22

1

1

—

,22 to 23

2.76 (0.62, 12.34)

4.47 (0.88, 22.74)

—

,23

4.62 (1.23, 17.28)

7.63 (1.80, 32.39)

—

1.17 (0.71, 1.95)

—

0.53 (0.16, 1.75)

0.92 (0.36, 2.36)

—

—

2.54 (1.48, 4.36)

3.50 (1.25, 9.77)

6.84 (1.25, 37.40)

CD4% (per 10)
Severe immunodeficiencyb
Hemoglobin ,8 g/dL
ART: antiretroviral treatment; HR: hazard ratio.
a
Among children ,10 years of age.
b
Defined by age according to the 2006 WHO guidelines.
doi:10.1371/journal.pone.0029294.t004

included younger age, severe undernutrition and severe anemia.
Interestingly, CD4+ T-cell percentage was not predictive of early
mortality, although the median CD4+ T-cell percentage was
relatively high in this group of children. These risk factors are
similar to risk factors for early mortality among children receiving
ART [3,25,26,27]. As a result of the late stage of disease at study
enrollment, most deaths occurred within the first few months of
follow-up before children could prepare for and start ART.
Consequently, continued efforts are needed to promote testing of
infants and children so that HIV-infected children can be
identified and enrolled into care at an earlier stage of disease. If
children could initiate treatment at lower levels of immunosuppression and with fewer concurrent illnesses, many of these preART deaths could be prevented.
There were several limitations to this study. First, the follow-up
time was relatively short and the number of observed deaths was
low, particularly among children ineligible for ART, which limited
our ability to evaluate risk factors for mortality in this group.
Second, study enrollment was used as a proxy for clinic
enrollment, as children had only been seen in the clinic for a
short duration prior to study enrollment. The reported mortality
rates may, therefore, underestimate the true mortality rate in this
population, as deaths may have occurred soon after clinic
enrollment which would not have been captured. However, the
loss to follow-up was low and it is unlikely that many deaths were
not reported. The mortality rate is likely to be accurate for the
group of children surviving long enough to enroll in the study.
Lastly, eligibility at study enrollment was defined retrospectively
based on immunologic and clinical criteria. Some misclassification
of eligibility status is likely to have occurred, as children with
undernutrition in this setting who are initially classified as WHO
stage 3 or 4 are not considered eligible for ART if they gain weight
on nutritional support and treatment. In addition, some children
were missing information on WHO stage or CD4+ T-cell
percentage at study enrollment and were classified based on
immunologic or clinical criteria alone.
In summary, a significant number of HIV-infected children
enrolled in treatment programs die before initiating ART as a

2.1 months. Other studies reported an average time of 4.7 months
to ART initiation among children in Cambodia [6], 0.9 months
among children in Lusaka, Zambia [3], one month among adults
in South Africa [7], and 4.3 months among adults in The Gambia
[11]. This period of preparation takes several clinic or home visits
to ensure caregivers are prepared to administer life-long
medication and be responsible for maintaining high adherence
in their children. This process can take longer in rural areas as
transportation and travel distance pose challenges, and necessitate
longer intervals between visits and synchronization of visits with
other family members [3]. Additional delays in ART initiation can
lengthen this period, and can be due to treatment for concurrent
tuberculosis or other illnesses, insufficient human resources
(primarily in the early years of a treatment program), incorrect
clinical or immunological staging by physicians, and social
problems in the family, such as lack of transportation, food
insecurity, no legal guardian, history of suboptimal adherence, lack
of disclosure of child’s status to another adult, denial of child’s
status or need for ART and ill health of the caregiver [6,21].
Similar reasons for delay were identified for 26.7% of children
eligible for ART at study enrollment in this study. Many of these
delays were warranted to stabilize the child’s health or ensure that
the family was prepared for the burden of administering ART to
the child. However, some delays also were attributable to clinician
judgment and could potentially be prevented through continued
training.
In this study, 77.8% of children who died were eligible for ART
and were therefore characterized by a younger age and later stage
of disease progression, including higher WHO stage, lower CD4+
T-cell percentage, lower WAZ, and lower hemoglobin. These
characteristics were well-established risk factors for mortality
among HIV-infected children in sub-Saharan Africa prior to the
availability of ART [22,23,24]. Many children enroll in treatment
programs when eligible for ART [3], as did 60% of children in this
study. Identification of risk factors for mortality that could
distinguish those children at risk of early death might allow for
interventions to halt disease progression and prevent death. In this
study, risk factors for mortality among children eligible for ART
PLoS ONE | www.plosone.org
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Figure 4. Cumulative probability of mortality by WAZ (A), hemoglobin level (B), and age (C) at study enrollment among children
eligible for ART.
doi:10.1371/journal.pone.0029294.g004

result of late-stage disease. These results further underscore the
need to increase efforts to identify HIV-infected children at an
earlier age and stage of disease so they can enroll in HIV care and
PLoS ONE | www.plosone.org

treatment programs prior to becoming eligible for ART. In this
way, they and their family can be prepared to initiate life-long
therapy and receive the full benefits of treatment.
8

December 2011 | Volume 6 | Issue 12 | e29294

Pre-Treatment Mortality in HIV-Infected Children

Acknowledgments

Author Contributions

We thank the children and their parents for participating in the study. We
thank the staff at the HIV clinic, the study team (Jeridy Munsanje,
Matthias Muleka, and Justin Moono) and the clinical research laboratory
staff (Jay Sikalima, Lushomo Chikobolo, and Michael Musonda) for their
assistance.

Conceived and designed the experiments: CGS JHvD WJM. Performed
the experiments: BM FH PS. Analyzed the data: CGS. Wrote the paper:
CGS. Supervised study conduct in Zambia: JHvD PET. Reviewed
manuscript: JHvD BM FH PS PET WJM.

References
1. WHO (2010) Towards Universal Access: Scaling up priority HIV/AIDS
interventions in the health sector. Progress Report 2010. Geneva, Switzerland:
World Health Organization.
2. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ (2008) Effectiveness of
antiretroviral therapy among HIV-infected children in sub-Saharan Africa.
Lancet Infect Dis 8: 477–489.
3. Sutcliffe CG, van Dijk JH, Bolton-Moore C, Cotham M, Tambatamba B, et al.
(2010) Differences in presentation, treatment initiation and response among
children infected with human immunodeficiency virus in urban and rural
Zambia. Pediatr Infect Dis J 29: 849–854.
4. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, et al.
(2008) Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir
Immune Defic Syndr 47: 615–622.
5. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, et al. (2009) Loss to care
and death before antiretroviral therapy in Durban, South Africa. J Acquir
Immune Defic Syndr 51: 135–139.
6. Raguenaud M-E, Isaakidis P, Zachariah R, Te V, Soeung S, et al. (2009)
Excellent outcomes among HIV+ children on ART, but unacceptably high preART mortality and losses to follow-up: a cohort study from Cambodia. BMC
Pediatr 9: 54.
7. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R (2005) Early mortality among
adults accessing a community-based antiretroviral service in South Africa:
implications for programme design. AIDS 19: 2141–2148.
8. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, et al. (2009) Mortality and
loss-to-follow-up during the pre-treatment period in an antiretroviral therapy
programme under normal health service conditions in Uganda. BMC Public
Health 9: 290.
9. Fairall LR, Bachmann MO, Louwagie GM, Van Vuuren C, Chikobvu P, et al.
(2008) Effectiveness of Antiretroviral Treatment in a South African Program: a
cohort study. Arch Intern Med 168: 86–93.
10. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants
of mortality and nondeath losses from an antiretroviral treatment service in
South Africa: implications for program evaluation. Clin Infect Dis 43: 770–776.
11. Togun T, Peterson I, Jaffar S, Oko F, Okomo U, et al. (2011) Pre-treatment
mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually
infected patients eligible for antiretroviral therapy in The Gambia, West Africa.
AIDS Res Ther 8: 24.
12. Marazzi MC, Germano P, Liotta G, Buonomo E, Guidotti G, et al. (2006)
Pediatric highly active antiretroviral therapy in Mozambique: an integrated
model of care. Minerva Pediatr 58: 483–490.
13. Charlebois ED, Ruel TD, Gasasira AF, Achan J, Kateera F, et al. (2010) Shortterm risk of HIV disease progression and death in Ugandan children not eligible
for antiretroviral therapy. J Acquir Immune Defic Syndr 55: 330–335.

PLoS ONE | www.plosone.org

14. van Dijk JH, Sutcliffe CG, Munsanje B, Hamangaba F, Thuma PE, et al. (2009)
Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional
analysis. BMC Infect Dis 9: 169.
15. van Dijk JH, Sutcliffe CG, Munsanje B, Sinywimaanzi P, Hamangaba F, et al.
(2011) HIV-infected children in rural Zambia achieve good immunologic and
virologic outcomes two years after initiating antiretroviral therapy. PLoS One 6:
e19006.
16. WHO (2006) Antiretroviral therapy of HIV infection in infants and children:
Towards universal access. Recommendations for a public health approach.
Geneva, Switzerland: World Health Organization.
17. WHO (2008) Report of the WHO Technical Reference Group, Paediatric
HIV/ART Care Guideline Group Meeting. Geneva, Switzerland: World
Health Organization.
18. The WHO child growth standards. Available at: http://www.who.int/childgrowth/
en/index.html. Accessed August 2005.
19. WHO (2001) Iron deficiency anaemia: assessment, prevention and
control. A guide for program managers. Geneva, Switzerland: World Health
Organization.
20. DHS (2002) Demographic and Health Survey Zambia Final Report 2001/02.
21. Feucht UD, Kinzer M, Kruger M (2007) Reasons for delay in initiation of
antiretroviral therapy in a population of HIV-infected South African children.
J Trop Pediatr 53: 398–402.
22. Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, et al. (2006)
Determinants of survival without antiretroviral therapy after infancy in HIV-1infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr
42: 637–645.
23. Sutcliffe CG, Scott S, Mugala N, Ndhlovu Z, Monze M, et al. (2008) Survival
from 9 months of age among HIV-infected and uninfected Zambian children
prior to the availability of antiretroviral therapy. Clin Infect Dis 47: 837–844.
24. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing
Committee (2008) Markers for predicting mortality in untreated HIV-infected
children in resource-limited settings: a meta-analysis. AIDS 22: 97–105.
25. The KIDS-ART-LINC Collaboration (2008) Low risk of death, but substantial
program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa.
J Acquir Immune Defic Syndr 49: 523–531.
26. Davies MA, Keiser O, Technau K, Eley B, Rabie H, et al. (2009) Outcomes of
the South African National Antiretroviral Treatment Programme for children:
the IeDEA Southern Africa collaboration. S Afr Med J 99: 730–737.
27. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM,
et al. (2007) Clinical outcomes and CD4 cell response in children receiving
antiretroviral therapy at primary health care facilities in Zambia. Jama 298:
1888–1899.

9

December 2011 | Volume 6 | Issue 12 | e29294

